首页> 外文期刊>Bone marrow transplantation >Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease.
【24h】

Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease.

机译:高危镰状细胞病患儿无关胎盘血细胞的移植。

获取原文
获取原文并翻译 | 示例
       

摘要

The lack of healthy HLA-identical sibs limits the use of allogeneic hematopoietic cell transplantation in children with high-risk sickle cell disease (SCD). We evaluated unrelated placental blood cell transplantation (UPBCT) after a preparative regimen of busulfan, cyclophosphamide and antithymocyte globulin in three children with SCD who had cerebrovascular accidents (CVAs) and did not have HLA-matched sib donors. The placental blood cell units were matched with the recipients at four of six HLA-A, HLA-B and HLA-DRB1 antigens. Neutrophil levels above 0.5 x 10(9)/l occurred at 23, 38 and 42 days after UPBCT, and platelet levels above 50 x 10(9)/l without transfusions occurred at 62, 81 and 121 days after UPBCT. All patients developed acute graft-versus-host disease (GVHD; two grade II, one grade III), and one developed extensive chronic GVHD. One patient had graft failure and autologous hematopoietic recovery. Two patients have complete donor hematopoietic chimerism without detectable hemoglobin S or symptoms of SCD at 40 and 61 months, respectively, after UPBCT. These observations demonstrate the feasibility of UPBCT in children with SCD. Further studies of UPBCT for SCD are needed but, because of risks of procedure-related morbidity and graft rejection, should be restricted to pediatric patients with high-risk manifestations of SCD.
机译:缺乏健康的HLA同胞同胞限制了高危镰状细胞病(SCD)儿童的异基因造血细胞移植的使用。我们在三例患有脑血管意外(CVA)且没有HLA匹配同胞供体的SCD儿童中,采用丁硫磺,环磷酰胺和抗胸腺细胞球蛋白的制备方案后,评估了无关的胎盘血细胞移植(UPBCT)。胎盘血细胞单位与六个HLA-A,HLA-B和HLA-DRB1抗原中的四个抗原的受体匹配。在UPBCT之后的23、38和42天,嗜中性粒细胞水平超过0.5 x 10(9)/ l,在UPBCT之后的62、81和121天,血小板水平在50 x 10(9)/ l以上而无输血。所有患者均发展为急性移植物抗宿主病(GVHD;两个II级,一个III级),其中一个发展为广泛的慢性GVHD。一名患者发生移植失败并自体造血恢复。在UPBCT后的40个月和61个月时,两名患者完全没有供血的造血嵌合症,也没有可检测到的血红蛋白S或SCD症状。这些观察结果证明了UPBCT在SCD儿童中的可行性。需要针对SCD进行UPBCT的进一步研究,但是由于与手术相关的发病率和移植物排斥反应的风险,应仅限于SCD高风险表现的儿科患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号